PinealonNootropic

Overview

Pinealon is a synthetic tripeptide, glutamate-aspartate-arginine (Glu-Asp-Arg / EDR), one of the "ultrashort peptide bioregulators" developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It is positioned as a neuro-active member of that family, alongside epitalon. Two facts must frame any honest reading: the entire usable evidence base is preclinical (cell and rodent), and it is dominated by a single research group with little independent replication. It is not FDA-evaluated and is sold only as a research chemical.

Mechanism

Pinealon has no identified receptor or validated molecular target. Its proposed mechanism comes from the broader Khavinson "peptide bioregulation" theory: short peptides are small enough to enter the nucleus and interact with histones and DNA, where they are proposed to modulate DNA methylation and gene expression. For EDR specifically, group publications describe binding to regulatory gene regions relevant to neuronal survival and antioxidant defense. Functionally, rodent studies show an antioxidant / neuroprotective profile. Whether this reflects a genuine direct epigenetic action remains unresolved, because the work has not been independently reproduced.

Clinical evidence

There is no independent human clinical-trial evidence for pinealon — no RCTs, no human pharmacokinetics, no peer-reviewed human efficacy or safety data. The evidence that exists is preclinical and largely single-group: in the most-cited study, maternal pinealon improved spatial learning and reduced oxidative neuronal damage in rat offspring exposed to prenatal hyperhomocysteinemia (Arutjunyan 2012), and Khavinson-group reviews describe EDR altering gene expression in cultured cells. These are hypothesis-generating findings; efficacy in humans is unestablished, and longevity/cognition claims are not backed by human studies.

Safety profile

Pinealon's human safety is effectively uncharacterized — no controlled human trials, no adverse-event data, no pharmacokinetics, no long-term follow-up. Rodent studies report apparent tolerability, but animal data do not establish human safety. A substance proposed to alter gene expression and DNA methylation warrants particular caution without long-term human data, and gray-market "research" material carries unverified identity, purity and sterility risks. It is not FDA-approved or a medicine, and not named on the WADA list (though novel peptides can fall under catch-all provisions). Given the YMYL stakes, both safety and human-data confidence are scored at the floor; nothing here is medical advice.

Compare

• vs Epitalon

  The most closely related Khavinson ultrashort-peptide bioregulator, sharing the same preclinical, single-group evidence pattern; Epitalon is framed around telomerase/aging where Pinealon is framed around neuroprotection.